The feasibility of classical cyclophophamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: A study of consistency in relative dose intensity (RDI) and cumulative doses across institutions

Annals of Oncology

Volumn 13, Issue 3, 2002, Pages 416-421

  Ferreira Filho, A F ^a   Di Leo, A ^a   Paesmans, M ^a   Beauduin, M ^a   Vindevoghel, A ^a   Michel, J ^a   Focan, C ^a   Awada, A ^a   Cardoso, F ^a   Dolci, S ^a   Bartholomeus, S ^a   Piccart, M J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Adjuvant chemotherapy; Breast cancer; Classical CMF; Feasibility

Indexed keywords

BENZAMIDE DERIVATIVE; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOPAMINE RECEPTOR BLOCKING AGENT; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PREDNISONE; PROCARBAZINE; SEROTONIN ANTAGONIST; TAMOXIFEN; VINCRISTINE; ANTINEOPLASTIC AGENT; CMF REGIMEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALOPECIA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; BREAST CANCER; CLINICAL TRIAL; COMMUNITY HOSPITAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; HUMAN; INFECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; BELGIUM; BREAST TUMOR; DISEASE FREE SURVIVAL; LYMPH NODE; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BELGIUM; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE;

EID: 0036018905     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf051     Document Type: Article

References (23)

1. Combination chemotherapy in the treatment of advanced Hodgkin's disease
2. Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard
3. Combination chemotherapy as an adjuvant treatment in operable breast cancer
4. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up
5. Polychemotherapy for early breast cancer: An overview of the randomised trials
6. Dose-response effect of adjuvant chemotherapy in breast cancer
7. Randomized trial of cyclophosphamide, methotrexate and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: A report of th
8. A randomized DBCG trial of adjuvant (adj) tamoxifen (TAM) plus radiotherapy (RT) versus TAM alone versus TAM plus CMF in postmenopausal breast cancer patients (pts) with high risk of recurrence
9. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial
10. 'Classical' CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group phase III trial (10808)
11. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: Cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference
12. CMF or anthracycline-based adjuvant chemotherapy for node-positive breast cancer patients: 4-year results of a Belgian randomised clinical trial with predictive markers analysis
13. The importance of dose intensity in chemotherapy of metastatic breast cancer
14. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer
15. Average relative dose intensity and the impact on design of clinical trials
16. Serotonin antagonists: A new class of antiemetic agents
17. Data and analysis having to do with the influence of dose intensity and duration of treatment (single drugs or combinations) on lethal toxicity and therapeutic response of experimental neoplasms
18. Are surgical adjuvant trials altering the course of breast cancer?
19. Confirmation of dose-survival relationship in breast adjuvant chemotherapy
20. Dose analysis for adjuvant trials in node-positive breast cancer. The ECOG trials
21. The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease free-survival
22. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer
23. Dose-response in the treatment of breast cancer: A critical review